JMW-3B3

Biotinylated JMW-3B3 (10 μg/mL) specifically detects sCTLA-4 in PBMC cell culture supernatants, and reveals no population-level difference in sCTLA-4 production between SLE patient and healthy donor PBMC stimulated with lupus-associated autoantigenic peptides^[1].
JMW-3B3 (10 μg/mL; 5 days) blocks sCTLA-4 activity in PBMC from both healthy donors and SLE patients, with effects that vary by stimulant: it suppresses some pro-inflammatory and proliferative responses in healthy donors, while enhancing IL-10 production (and altering proliferation/cytokine profiles) in SLE patient PBMC, accentuating the inherent cytokine response differences between the two groups^[1].
JMW-3B3 (20 μg/mL; overnight at 4°C) selectively binds intracellular sCTLA-4 in G-361 human malignant melanoma epithelial cells, but does not detect sCTLA-4 in A-375 human malignant melanoma epithelial cells^[2].
JMW-3B3 (10 μg/mL; 5 days) enhances IFN-γ production from melanoma patient PBMC stimulated with a low dose (0.02 μg/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment^[2].
JMW-3B3 (10 μg/mL; 5 days) enhances IL-17A production from healthy donor PBMC stimulated with a high dose (1 μg/mL) of anti-CD3 mAb for 5 days, relative to ipilimumab treatment^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.